Cassava Sciences Announces New Patent Grant
Cassava Sciences’ lead drug candidate, sumifilam, is a novel molecule. The Company’s patent protection in the area of filamin-binding molecules currently runs through 2037, plus extensions, and now includes seven issued patents plus related patent filings and applications.
Sumifilam was discovered in-house.
About Alzheimer's Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. In the
About Sumifilam (formerly, PTI-125)
Cassava Sciences’ lead therapeutic product candidate is for the treatment of Alzheimer’s disease. Sumifilam is a proprietary, small molecule (oral) drug that restores the normal shape and function of altered filamin A (FLNA), a scaffolding protein, in the brain. Altered FLNA in the brain disrupts the normal function of neurons, leading to Alzheimer’s pathology, neurodegeneration and neuroinflammation. The underlying science is published in peer-reviewed scientific journals, including
About SavaDx
SavaDx is Cassava Sciences’ investigational diagnostic to detect Alzheimer’s disease. The goal of SavaDx is to make the detection of Alzheimer’s as simple as getting a blood test, possibly years before the appearance of any overt clinical symptoms.
About
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years,
For more information, please visit: https://www.CassavaSciences.com
For More Information Contact:
eschoen@CassavaSciences.com
(512) 501-2450
________________
1, 2 Source: Alzheimer’s Association. 2019 Alzheimer’s Disease Facts and Figures. Available online at: https://www.alz.org/media/documents/alzheimers-facts-and-figures-2019-r.pdf
Source: Cassava Sciences, Inc.